Objective. Bone marrow-derived mesenchymal stem cells (BM-MSCs) create a special microenvironment for hematopoiesis and immunity and display robust immunomodulatory properties that are impaired in systemic lupus erythematosus (SLE). This study was undertaken to identify the mechanisms of defects in human SLE BM-MSCs.
increased DNA damage and repair, increased expression of p53 and p16, which block the cell cycle, and altered cytokine production (increased proinflammatory cytokine production and decreased immunomodulatory cytokine production). Moreover, SLE BM-MSCs had a 5-fold increase in interferon-b (IFNb) levels (P < 0.05 versus healthy controls) and increased IFNb-induced messenger RNAs (mRNAs), including mRNA for the intracellular nucleic acid-sensing adaptor protein mitochondrial antiviral signaling protein (MAVS), whose expression was highly correlated with IFNb levels (r > 0.9, P < 0.01). Since MAVS is known to induce IFNb production, we hypothesized that there is a positive feedback loop between MAVS and IFNb. Notably, silencing of MAVS markedly decreased IFNb, p53, and p16 protein levels and expression of mRNAs for proinflammatory cytokines.
Conclusion. This study demonstrates a novel pathway for elevated IFNb signaling in SLE that is not dependent on stimulation by immune complexes but rather is cell intrinsic and critically mediated by IFNb and MAVS, implicating new pathways as potential therapeutic targets.
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with substantial morbidity and mortality that disproportionately affects young women. SLE pathogenesis is characterized by autoantibody production, immune complex formation, and systemic or organ-specific inflammation (1) . Bone marrow-derived mesenchymal stem cells (BM-MSCs) provide a supportive microenvironment for the maintenance of hematopoietic stem cells and for hematopoiesis. BM-MSCs are also capable of differentiating into various cell types, such as bone, fat, and cartilage. In recent years, human MSC transplantation has become an interesting but controversial approach to treating SLE and other human autoimmune diseases (2) . MSC transplantation in murine models of lupus has been promising (3) , and the immunomodulatory potential of human MSCs has been clearly demonstrated in these murine models (4) . Open trials of MSC transplantation in humans have also shown promise, but well-controlled clinical trials are lacking (5) . Interestingly, MSCs from humans with lupus are abnormal, and even the earliest studies have indicated that these abnormalities might be related to the pathogenesis of the disease (6) . BM-MSCs from humans with lupus and from murine models of lupus do not grow well, show evidence of senescence, and have poor immunomodulatory capacity compared to BM-MSCs from healthy controls (6, 7) . The aim of the present study was to determine the mechanism of BM-MSC abnormalities, and, in particular, the role of type I interferon (IFN), in SLE.
A predominant paradigm in SLE research is that self-nucleic acids, particularly when oxidized or complexed with autoantibodies, stimulate leukocytes via Fc receptor (FcR)-mediated uptake and ligation of Toll-like receptor 7 (TLR-7), TLR-8, and TLR-9 in endocytic vesicles (8) . Chronic TLR stimulation is presumed to drive ongoing elevation in type I IFN production, particularly IFNa, in turn driving elevated levels of type I IFN biologic activity in serum and a type I IFN signature in peripheral blood leukocytes (9, 10) . However, in human clinical trials, blocking of IFNa has led to only limited inhibition of the IFN signature and no or limited clinical efficacy (11, 12) . Trials of agents that block the type I IFN receptor have been more successful in blocking the IFN signature, and preliminary studies suggest clinical efficacy (13) .
The type I IFN system consists of multiple isotypes (13 IFNa, 1 IFNb, 1 IFNd, 1 IFNk, and 1 IFNv), which all bind to the same type I IFN receptor (14) . IFNa and IFNb are the best studied of the type I IFNs. They both induce antiviral responses, but IFNb binds with a much higher affinity to the type I IFN receptor and induces unique antiproliferative and immunomodulatory effects in a cell type-specific and "tunable" manner (15) . For example, IFNb has been shown to induce reactive oxygen species (ROS), DNA damage, and p53-dependent cellular senescence, properties not shared by IFNa (16) . Constitutive production of IFNb also plays an important role in priming the immune system (17), e.g., regulating the response to TLR-4 ligands by macrophages, response to TLR-7 ligands by B cells, and IFNa production by fibroblasts (18, 19) . Originally known as fibroblast IFN, IFNb is the major IFN produced by mesenchymal cells. Thus, it seemed possible that some of the defects in SLE MSCs could be related to IFNb. Of note, modular transcriptome repertoire analysis provided evidence of IFNb production in some patients with SLE (20, 21) . For example, module 3.4 is increased in peripheral blood cells from a subset of SLE patients (20, 21) . Module 3.4 is not up-regulated by IFNa in patients with hepatitis C but is up-regulated in multiple sclerosis patients receiving IFNb (21) .
Although FcR and endosomal TLRs (especially TLR-7 and TLR-9) are important in triggering IFN production by leukocytes, different mechanisms are involved in triggering IFN production by non-leukocytes such as MSCs. Mitochondrial antiviral signaling protein (MAVS), also known as IFNb promoter stimulator protein 1, is a strong stimulator of IFNb in a variety of cell types. MAVS is an adaptor protein linking cytoplasmic sensors of nucleic acid such as retinoic acid-inducible gene 1 (RIG-1) and melanoma differentiation-associated protein 5 (MDA-5) with production of IFN and activation of NF-kB. Overexpression of MAVS constitutively stimulates type I IFN and type I IFN-stimulated genes (22) . MAVS is critical for host defenses and IFN production in responses to RNA viruses. In addition, IFNb can be triggered in response to cytosolic DNA by signaling involving RNA polymerase III, RIG-1, and MAVS (23) . A gain-of-function mutation of MDA-5 has been associated with risk of SLE (24) , and MAVS polymorphisms have been linked to manifestations of SLE in a Chinese population (25) .
The present study focuses on the intrinsic BM-MSC defects in SLE and the underlying mechanisms of these defects. We describe striking abnormalities in MSCs isolated from SLE BM, with several features of cellular senescence, including decreased replication, evidence of DNA damage, increased ROS, high levels of cell cycle arrest proteins p53 and p16, and increased senescence-associated proinflammatory cytokines. Further, IFNb and MAVS both mediate these defects via a positive feedback loop, as silencing of MAVS completely reverses the senescent phenotype.
PATIENTS AND METHODS
Human BM-MSC isolation and culture. Detailed written informed consent was obtained from all patients and healthy donors, in accordance with protocols approved by the Human Subjects Institutional Review Board of the University of Rochester Medical Center. SLE patients fulfilled the American College of Rheumatology classification criteria (26) . Clinical data included a comprehensive medical history, medications profile, clinical laboratory tests, and assessment of SLE disease activity by SLE Disease Activity Index (27) ( Table 1) . Research BM aspirates were obtained from 6 SLE patients and 6 healthy controls as previously described (28) . Genomic samples from SLE patients were genotyped at the rs11905552 site in the MAVS gene for the C79F MAVS single-nucleotide polymorphism (SNP) (29) . BM-MSCs were isolated from the BM of healthy donors and SLE patients using Ficoll Premium (1.073 gm/ml). Ten milliliters of BM samples was diluted with 2 parts of phosphate buffered saline (PBS) and then 12 ml of Ficoll Premium (1.073 gm/ml) was placed underneath. The mixture was centrifuged at room temperature at a relative centrifugal force of 400g for 30 minutes. The BM-MSC layer was removed, washed, plated in a 6-well plate, and cultured at 378C in 5% oxygen. Medium was changed every other day until the cells reached 80% confluence.
Western blotting. Western blotting was performed as previously described (30) . The antibodies used included IFNb, MAVS, p53, p16, 53BP1, and actin (Thermo Fisher Scientific).
Quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA from cultured cells was isolated using an RNeasy kit (Qiagen). Total RNA (1 mg) from cells or articular tissue was reverse transcribed into complementary DNA using an iScript cDNA Synthesis kit (BioRad). Real-time PCR was performed on a Rotor-Gene 6000 real-time DNA amplification system (Qiagen) using PerfeCTa SYBR Green Supermix (Quanta BioSciences) according to the manufacturer's instructions. See Supplementary Immunofluorescence labeling. Human BM-MSCs were cultured in chamber slides for 24 hours. After washing with PBS, the cells were fixed with 4% paraformaldehyde at 48C for 1 hour. The cells were incubated with antibodies against histone gH2AX and pATM (Fisher Scientific) diluted in PBS containing 5% bovine serum albumin and 0.5% Tween 20, and further incubated at 48C for 12 hours. This was followed by incubation with a fluorophore-conjugated secondary antibody (Jackson ImmunoResearch) at room temperature for 1 hour. The chamber slides were rinsed with water, air-dried, and mounted with Vectashield (Vector).
Comet assay. A comet assay was performed as previously described (31) . Briefly, MSCs from healthy controls and SLE patients were isolated from BM and subjected to neutral lysis and electrophoresis for detection of DNA double-strand breaks. Slides were stained with DAPI before analysis.
Beta-galactosidase assay. A b-galactosidase (b-gal) assay was performed using a b-gal assay kit (Thermo Fisher Scientific) according to the manufacturer's protocol.
Flow cytometric analysis. Single-cell suspensions of BM-MSCs (10 6 /sample) were labeled at 48C with predetermined optimal concentrations of fluorophore-conjugated monoclonal antibodies against CD34, CD45, CD73, CD90, CD105, CD31, CD19, CD11b, HLA-A/B/C, CD44, CD29, and HLA-DR surface markers (eBioscience). Pair-matched isotype controls were also used. ROS was detected using CellROX (Thermo Fisher Scientific). Ki-67 was used for proliferation analysis according to the manufacturer's protocol (eBioscience).
Cytokine enzyme-linked immunosorbent assay (ELISA). Interleukin-6 (IL-6), IL-8, and granulocyte-macrophage colonystimulating factor (GM-CSF) levels in the supernatants of BMMSCs were evaluated with human IL-6, IL-8, and GM-CSF immunoassay kits (R&D Systems) following the manufacturer's protocol.
Statistical analysis. Data are the mean 6 SEM. Statistical significance was determined by Student's t-test or as indicated in the figure legends. P values less than 0.05 were considered significant.
RESULTS
SLE BM-MSCs display MSC markers and behavior. BM-MSCs were isolated with Ficoll from the BM of healthy donors and SLE patients. It has been reported that the C79F MAVS SNP leads to a MAVS loss-of-function mutation by impairing MAVS-tumor necrosis factor receptor-associated factor 3 interaction, and this mutation is more frequent in individuals of African origin (32) . Therefore, the genomic samples from SLE patients were genotyped at the rs11905552 site in the MAVS gene for the C79F MAVS SNP (29) . No C79F MAVS SNP was found in the SLE patients in this study (data not shown), ruling out the possibility that the MAVS loss-of-function mutation could have contributed to the phenotypes observed in the present work. To identify the cell types isolated, the cells were phenotyped by flow cytometric analysis of cell surface markers. More than 95% of the isolated second-passage cells were positive for CD73, CD90, and CD105 and negative for CD34 and CD45 ( Figure 1A ). In addition, further analysis revealed that the isolated cells were also positive for CD29, CD44, and HLA-A/B/C and negative for CD31, CD11b, CD19, and HLA-DR (Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40142/abstract). No difference in the MSC surface markers was observed between healthy donors and SLE patients. When the isolated cells were plated on cell culture discs, they adhered to the plastic surface in spindle shapes ( Figure 1B) . To assess the differentiation potential of these cells, conditional medium for osteogenesis, chondrogenesis, or adipogenesis was applied. At the end of the induction, the isolated cells were stained with alkaline phosphatase, Alcian blue, or oil red O to identify differentiation to these respective cell lineages (Figure 1C) . Taken together, these findings indicate that the isolated cells are MSCs with MSC cell surface markers and 3 lineage differentiation potentials.
Activation of DNA damage and repair pathways by DNA double-strand breaks in SLE BM-MSCs. Given that DNA damage and aberrant DNA products have been found in the serum of SLE patients (33), we next evaluated DNA double-strand breaks in BM-MSCs using a comet assay (Figure 2A ). SLE BM-MSCs had 5-fold more comet tail moments than healthy controls (Figure 2A ), suggesting that SLE BM-MSCs have more DNA double-strand breaks. We then investigated the cell response to the DNA double-strand breaks: the DNA damage and repair pathways. Immunofluorescence imaging demonstrated that the phosphorylation of the histone variant H2AX, an early and specific DNA damage marker, was strongly activated in SLE BMMSCs ( Figure 2B ). ATM is a key mediator in DNA damage and repair pathways, becoming phosphorylated upon activation. The pATM immunofluorescence staining demonstrated that ATM was activated in SLE BMMSCs ( Figure 2C ). Levels of 53BP1, a DNA damage and repair protein found in persistent DNA damage foci (34), were increased in SLE BM-MSCs ( Figure  2D ). These findings demonstrate that persistent DNA double-strand breaks activate the DNA damage and repair pathway in SLE BM-MSCs.
SLE BM-MSCs undergo senescence and have reduced immunomodulatory function. Given that DNA damage accumulation can result in senescence and senescence-related secretory phenotypes, we next evaluated SLE BM-MSC senescence and senescenceassociated secretory phenotype. Since growth arrest is a hallmark of senescence, proliferation was assessed by determining Ki-67 expression using flow cytometry ( Figure 3A) . SLE BM-MSCs had a significantly reduced percentage of proliferating cells when compared to healthy controls, suggesting growth arrest in SLE BMMSCs. A number of proteins compatible with senescence induction, including p53 and p16, were markedly increased in SLE BM-MSCs ( Figure 3B ). Senescence is also associated with senescence-associated b-gal expression (35) . In the healthy controls, senescence-associated b-gal-positive cells were barely detected, as compared to the markedly elevated senescence-associated b-gal activity in SLE BM-MSCs ( Figure 3C ).
The senescence-associated secretory phenotype indicates a phenomenon whereby senescent cells increase the expression and secretion of certain cytokines, chemokines, and other proteins (36) . Notably, expression of senescence-associated secretory phenotype-related genes (IL-6, IL-8, growth-related oncogene 1, monocyte chemotactic protein 2, RANTES, and GM-CSF) was significantly higher in SLE BM-MSCs than in healthy controls ( Figure 3D ). When IL-6, IL-8, and GM-CSF in the supernatant were evaluated by ELISA, increased concentrations of these cytokines were observed in the supernatant of SLE BM-MSCs compared to healthy controls Figure 3E ). Taken together, these findings demonstrate that SLE BM-MSCs undergo senescence and have impaired immunomodulatory function.
Activation of the nucleic acid-sensing protein MAVS and its target IFNb in SLE BM-MSCs. It has been reported that MAVS plays an important role in the senescence-associated secretory phenotype in contexts other than SLE. When MAVS was silenced in senescent human umbilical vein endothelial cells, expression of IL-6 and IL-8 was suppressed (37) . Therefore, we evaluated MAVS in SLE BM-MSCs. MAVS expression was significantly elevated in SLE BM-MSCs ( Figure 4A ). As an IFNb stimulator, MAVS protein activates IFNb production (38) . RT-PCR and Western blotting results revealed that IFNb expression was dramatically up-regulated in SLE BM-MSCs ( Figure 4A) . Notably, the expression levels of MAVS and IFNb were highly correlated (r . 0.9, P , 0.01) ( Figure 4B ).
IFNb and IFNa are both type I IFNs that comprise the type I IFN signature in SLE. We next evaluated 1628 GAO ET AL Figure 3) . Next, we compared the IFNb-specific genes in healthy versus SLE BM-MSCs. These IFNb-specific targets were markedly up-regulated in SLE BM-MSCs ( Figure 4C ). Because the activation of both MAVS and IFNb is linked to ROS production and DNA damage (16, 39) , we also evaluated the ROS level in SLE BM-MSCs. SLE BM-MSCs had 2-fold more ROS than healthy controls ( Figure 4D ). These findings suggest that the nucleic acid sensor MAVS is activated in SLE BM-MSCs, and that MAVS together with IFNb and ROS may be key regulators of DNA damage and senescence in SLE BM-MSCs.
Silencing of MAVS blocks IFNb expression, reduces senescence-associated secretory phenotype-related cytokine production, and improves immunomodulatory factor expression in SLE BM-MSCs. To further explore the role of MAVS in the senescence-associated secretory phenotype of SLE BM-MSCs, MAVS small interfering RNA (siRNA) was introduced into both healthy and SLE BM-MSCs. MAVS expression was significantly silenced following siRNA application ( Figures 5A and C) . In addition, silencing of MAVS led to inhibition of IFNb expression ( Figures 5B and C) . More surprisingly, the senescencecompatible proteins p53 and p16 were blocked following application of MAVS siRNA ( Figure 5C ). Senescenceassociated secretory phenotype-related cytokine production was also inhibited ( Figure 5D 
DISCUSSION
The present work demonstrates for the first time that SLE BM-MSCs have a proinflammatory and senescenceassociated phenotype that is mediated by a MAVS and IFNb feedback loop. Compared to healthy controls, SLE BM-MSCs produced increased amounts of IFNb and had increased messenger RNA (mRNA) for genes induced specifically by IFNb rather than IFNa. They also had decreased proliferation, increased ROS, increased DNA damage and repair, a senescence-associated secretory phenotype, and increased levels of senescence-associated b-gal. MAVS mRNA was induced by IFNb, and there was a very strong correlation between levels of MAVS mRNA and IFNb mRNA. MAVS was originally characterized based on its ability to induce IFNb, setting up the potential for an IFNb-MAVS-mediated positive feedback loop promoting cellular senescence. Silencing of MAVS disrupts the IFNb positive loop by down-regulating IFNb and p53 and p16 proteins, and inhibits the expression of proinflammatory cytokines in SLE BM-MSCs. These results establish the critical role of an IFNb-MAVS positive feedback loop in SLE and provide a strong rationale for targeting this feedback loop in SLE and potentially other autoimmune diseases.
A distinguishing function of IFNb is the induction of ROS, double-strand breaks, DNA repair mechanisms, and cellular senescence (16, 40) . Exogenously added IFNb has been found to induce double-strand breaks and senescence in cell lines (16) . Similarly, endogenously produced IFNb can play an important role in senescence as well, e.g., anti-human IFNb antibodies rescued normal fibroblasts as well as fibroblasts from patients with Werner syndrome (a type of adultonset progeria) from replicative senescence, decreased protein markers of DNA damage and senescence (p53 and p16), and reduced expression of the senescenceassociated marker b-gal (40) . Conversely, double-strand DNA breaks from radiation, genotoxic agents, or genetic manipulation stimulate IFNb secretion (40) . Thus, a DNA damage-IFNb feedback loop with the potential to promote and perpetuate inflammation and cellular dysfunction has previously been described in several other systems, but as far as we know not in SLE. In this study we provide evidence of similar senescenceassociated processes and IFNb production in BMresident MSCs from SLE patients, strongly suggesting that targeting IFNb may reverse some of these abnormalities. Indeed, silencing of MAVS, the primary inducer of IFNb in many cell types, blocked IFNb production and reversed several of the molecular markers of senescence.
The molecular epidemiology of SLE suggests a role of cytoplasmic sensing of nucleic acids in pathogenesis. A gain-of-function mutation of MDA-5 has been associated with an increased risk of SLE (24) , and MAVS polymorphisms have been linked to different manifestations of SLE in Chinese patients (25) . Moreover, prion-like MAVS aggregation was found in the peripheral blood of a subset of lupus patients with increased type I IFN levels (41) . A MAVS loss-offunction mutation has been reported in 27.6% of a subSaharan African population, 1.7% of Europeans, and 9.4% of African Americans (32) . This mutation was present in 12.6% of African American patients with SLE. These African American SLE patients had lower levels of type I IFN (P 5 0.0032), and the percentage of patients who lacked autoantibodies against RNA binding proteins was increased (odds ratio 2.6; P 5 0.00084). In animal studies MAVS and IFNb were found to be essential for the expression and function of TLR-7 in B cells, and TLR-7 has been shown to be essential for the generation of antibodies against RNA binding proteins (18, 42) . Thus, lack of autoantibodies against RNA binding proteins in African American lupus patients with the MAVS loss-of-function mutation may be secondary to a defect in expression of TLR-7 in B cells.
A role of intracellular nucleic acid sensing in idiopathic lupus is also suggested by the association of SLE with a mutation in the 3 0 DNA repair exonuclease TREX1 (43) . Mutations in TREX1 lead to increased cytosolic DNA and activation of the stimulator of IFN genes (STING) pathway. Moreover, the activation of mutations of STING, another molecule involved in cytoplasmic sensing of nucleic acids, has been associated with an inflammatory syndrome having some lupus-like features (44) . Thus, there are hints from the literature that cytoplasmic sensors of nucleic acids may be important in the pathogenesis of SLE. In this study we have directly demonstrated a critical role of MAVS in the activation of and IFNb production by SLE BM-MSCs.
BM-MSCs play an important role in bone and cartilage metabolism by differentiating into osteoblasts and chondrocytes and are critical for the development of hematopoietic stem cells into blood and lymphoid cells. Thus, BM-MSC abnormalities in SLE patients may be directly related to an increased risk of osteoporosis and avascular necrosis of bone (45) . In addition, SLE BM-MSCs may have cell non-autonomous effects on the microenvironment due to their reduced immunomodulatory capacity, as suggested by the downregulation of immunomodulatory factors (TGFb, IDO-1, and LIF). However, Opitz et al (46) reported a novel finding that TLR enhances the immunosuppressive function of MSCs by activating IDO-1 via IFNb. They also noted that this finding contradicted the findings of a previous study by Liotta et al (47) , possibly due to a shorter exposure time of MSCs to TLR ligand. In our studies, BM-MSCs from lupus patients would have been chronically stimulated in vivo. Thus, it is not surprising that our results are similar to those of Liotta et al, and that long-term stimulation suppressed IDO-1 expression in lupus BM-MSCs.
Thus, alterations in BM-MSC function in SLE may jeopardize the BM microenvironment, potentially skewing hematopoiesis and altering immune responses. Indeed, there are published reports of increased levels of ARID3a, a protein induced by IFNb but not IFNa, in B cells from a subset of patients with SLE (48) . ARID3a has been linked to development of B-1 cells in mice, and hematopoietic stem cells from SLE patients with high levels of ARID3a in B cells when transferred to mice produced increased levels of autoantibodies (48) . Moreover, innate and type I IFN pathways are markedly up-regulated in B cells with high levels of ARID3a (49) . We found that ARID3a was up-regulated in BM-MSCs, and ARID3a mRNA was down-regulated in addition to IFNb mRNA when MAVS was silenced. We speculate that IFNb production in the BM microenvironment is also responsible for the induction of ARID3a in hematopoietic stem cells and B cells and that BM-MSCs are an important source of IFNb.
Taken together, our findings show increased IFNb production in SLE BM-MSCs and indicate that MAVS acts as a critical player by regulating IFNb production, with an IFNb-MAVS positive feedback loop (Supplementary Figure 5) . We propose that IFNb and its target gene products contribute to chronic inflammation and ROS, damaging DNA which is then sensed by MAVS. In turn, MAVS stimulates the IFNb promoter and increases IFNb expression and secretion, which further contributes to chronic inflammation and ROS generation. Under the influence of this IFNb positive feedback loop, cells eventually exit the cell cycle and undergo senescence but continue to release IFNb and other inflammatory factors altering adjacent cells and the BM microenvironment. This IFNb-MAVS feedback loop in BM-MSCs has the potential to alter the development of immune cells in the BM and contribute to SLE pathogenesis. In ongoing work we will explore where other cell types in SLE are similarly activated and potentially contribute to accelerated development of inflammation, degenerative disease, and organ dysfunction in SLE (50) .
